dr. Nick Verougstraete (PhD)

CRIG member
Nick Verougstraete

Clinical biologist – Toxicology lab (Department of laboratory medicine, UZ Gent)

Research focus

My research focuses on therapeutic drug monitoring (TDM) of anticancer drugs: tyrosine kinase inhibitors used for treatment of CML/AML/CLL and busulfan-fludarabine used in allogeneic hematopoietic stem cell transplantation. TDM of anticancer treatment is not yet routinely performed, although it offers a high potential to improve treatment outcome and minimize toxicity. In other words, it is vital for personalized cancer treatment. We develop analytical methods for the quantification of these drugs in regular plasma and in alternative samples, such as dried blood microsamples which enable (home) sampling by the patients themselves. Measured concentrations are correlated with clinical status of the patient, molecular response, presence of adverse effects,… The methods can also be used in clinical routine practice.


  • 2023: obtained a PhD, entitled 'Microsampling at home: a patient-centric approach to monitor cancer therapy and diabetes'.

Key publications

  • Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS/MS method. Talanta, 2021. (PMID: 33676691)
  • Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples. Front Oncol., 2022. (PMID: 35392223) 
  • Automation in Busulfan Therapeutic Drug Monitoring: Evaluation of an Immunoassay on two Routine Chemistry Analyzers. Ther Drug Monit., 2022. (PMID: 34985848)
  • Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors. J Pharm Biomed Anal., 2022 (PMID: 34655987)

Contact & links

  • Lab address: Campus UZ Gent, Corneel Heymanslaan 10, 9000 Gent
  • Nick Verougstraete is interested to receive invitations for presentations or talks